BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Aptuit, Inc. and Aegerion Pharmaceuticals, Inc. (AEGR) Sign Commercial API Supply Agreement


1/8/2013 11:17:52 AM

GREENWICH, Conn., Jan. 8, 2013 /PRNewswire/ -- Stuart Needleman, President and Chief Operating Officer, Aptuit LLC, announced that Aptuit and Aegerion Pharmaceuticals, Cambridge, Massachusetts, have signed a long-term supply agreement for commercial quantities of the active pharmaceutical ingredient (API) lomitapide.

(Logo: http://photos.prnewswire.com/prnh/20120217/NY55633LOGO )

Lomitapide is Aegerion's orphan drug that is targeted to the treatment of a rare disease caused by a genetic disorder. The drug received NDA approval in December of 2012 and is expected to be launched commercially in January of 2013. Previously, Aptuit scientists had established the chemistry for lomitapide, developed and validated its analytical methods, delivered solid state form control and crystallization R&D, and supplied registration batches of material. Post-launch, Aptuit will continue to supply commercial quantities of lomitapide to Aegerion.

Mr. Needleman explained, "Because of the drug's orphan status and high unmet medical need of the patients, on time and in full delivery of the API is crucial. Collaboration across several Aptuit sites in the US and Europe has made this possible. By accessing the vast drug development expertise of our organization, we have been able to accelerate the delivery of materials, methods, solid state chemistry and regulatory documentation and help the client win prompt NDA approval."

Although the exact terms of the agreement were not disclosed, Mr. Needleman added, "The collaboration represents another good example of how Aptuit's integrated, global drug development capabilities can have a direct, positive impact on the pharmaceutical industry."

Press Contact:
Maria Garvey, Media Manager, Delfino Marketing, 914-747-1400

Aptuit Contact:
Jennifer Demaree, Senior Manager, Marketing & Communications, 203-660-6016

Aptuit LLC provides the most complete set of integrated early to mid-phase development services in the pharmaceutical industry. Drug Design & Discovery, Preclinical Biosciences, API Development and Manufacture, Solid State Chemistry, Drug Product Formulation Development & Manufacture, Sterile Fill Finish, Clinical Sciences, Consulting and Aptuit INDiGO®(a program that accelerates drug development) are offered as stand alone or integrated services. Fully integrated drug discovery & development services are available from a single site at The Aptuit Center for Drug Discovery & Development in Verona, Italy.

The company maintains five global facilities with approximately 800 employees in Europe and the United States, and has a strategic relationship with Laurus Labs in India. Aptuit LLC is partnered with Welsh, Carson, Anderson & Stowe, one of the world's leading private equity investors.

For more information about Aptuit, visit www.aptuit.com

SOURCE Aptuit LLC



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->